Latest Breaking News On - Gain therapeutics - Page 14 : comparemela.com

Gain Therapeutics (GANX) Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of GT-02287

Gain Therapeutics (GANX) Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of GT-02287
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Joanne taylorSusan sharpeMatthias alderMovement disordersResearch at gainDrug administrationInternational congressGain therapeutics incExchange commission onExchange commissionCompany annual report on formLinnden communicationsGain therapeuticsNeurofilament light chainSenior vice presidentLate breaker abstract

Gain Therapeutics, Inc Expected to Post Q1 2024 Earnings of ($0 46) Per Share (NASDAQ:GANX)

Gain Therapeutics, Inc Expected to Post Q1 2024 Earnings of ($0 46) Per Share (NASDAQ:GANX)
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United kingdom generalUnited kingdomGain therapeutics incDimensional fund advisorsGain therapeutics company profileNewedge advisorsSusquehanna international groupBlackrock incGain therapeuticsFree reportGain therapeuticChardan capitalEdge advisorsStreet groupFund advisorsInternational group

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s Disease and Movement Disorders® in Copenhagen, Denmark BETHESDA, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today annou

Matthias alderSusan sharpeLinnden communicationsGain therapeutics incMovement disordersHuman research ethics committeeInternational congressExchange commissionCompany annual report on formExchange commission onChief executive officerLate breaker abstractMonths ended juneGain therapeuticsPrivate securities litigation reform actAnnual report

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson s Disease and Movement Disorders®

BETHESDA, Md., Aug. 07, 2023 Gain Therapeutics, Inc., , a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today.

Susan sharpeMatthias alderJoanne taylorInternational congressGain therapeutics incMovement disordersResearch at gainLinnden communicationsLate breaker abstractSenior vice presidentGain therapeutics

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson s Disease and Movement Disorders

07.08.2023 - BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) - Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late .

Matthias alderJoanne taylorSusan sharpeGain therapeutics incLinnden communicationsResearch at gainLate breaker abstractSenior vice presidentGain therapeutics